AMANDA CROWLEY: Open Payments
NPI 1326867698 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$992 in 54 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $324 · 2025 $992
Food & beverage: $992
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $145 |
| Lilly USA, LLC | 5 | $100 |
| Amgen Inc. | 6 | $98 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $91 |
| GlaxoSmithKline, LLC. | 4 | $84 |
| AstraZeneca Pharmaceuticals LP | 5 | $73 |
| PFIZER INC. | 4 | $66 |
| Axsome Therapeutics, Inc. | 2 | $64 |
| Organon LLC | 2 | $48 |
| Lundbeck LLC | 3 | $48 |
Products named: MOUNJARO, Ozempic, Kerendia, TRELEGY ELLIPTA, OTEZLA, Auvelity, Wegovy, NEXPLANON.
Industry payments across IN — which companies pay providers there.
